Mr. Bedford brings his expertise in business and finance to Zymeworks, after serving as Chairman of the Board of Directors of ActiveState Corporation, a software corporation, up to the time of its acquisition by Sophos Group plc an international security software and hardware company. Additionally, he has held senior positions at UBS Warburg, including the Frankfurt-based role as Head of German Equities. In this position he oversaw all sales and sales trading of equity products, and was responsible for the merger of UBS Germany’s equity business with SBC Warburg. Prior to this he was with UBS’ Securities division in Zurich, Tokyo, and London. Mr. Bedford currently serves on the Board of Actenum Corporation. Mr. Bedford holds a B.Sc. in Civil Engineering from King’s College, London University. Mr. Bedford has served as a member of our board of directors since September 20, 2004. He is also currently serving as a director of Acentum Corporation.
Board of Directors
Dr. Blanchard is currently Eli Lilly & Co.’s Senior Vice-President of Medicines Development Unit and Vice President of Tailored Therapeutics. Dr. Blanchard received a BS degree in chemistry in 1977, a PhD in Biochemistry in 1982 and an MD in 1985 from Indiana University. He completed a residency in Internal Medicine and fellowships in Hematology and Medical Oncology at the Brigham and Women’s Hospital, the Dana Farber Cancer Center, and Harvard Medical School in 1990. Prior to joining Lilly in 2000, he was a tenured Professor of Medicine and Biochemistry & Molecular Biology at Louisiana State University Health Sciences Center in Shreveport, Louisiana. He has played multiple roles in Lilly Research Laboratories including Senior Clinical Research Physician in Program Phase Oncology, Chief Scientific Officer Cancer Discovery, Executive Director of Cancer Discovery & Lilly Systems Biology-Singapore and Chief Operating Officer/Vice-President of Discovery Research and Vice-President of Integrative Biology.
He has served on the Board of Directors of the Lilly Singapore Centre for Drug Discovery and Systems Biology. He is a co-founder and a member of the Board of Directors of the Asian Cancer Research Group, and he serves on the Board of Directors of the Lilly Suzhou Pharmaceutical Company. Dr. Blanchard has served as a member of our board of directors since June 24, 2015.
Mr. Hall is a consultant to the life sciences industry with over 25 years of experience in the biotechnology sector. He was the Co-founder, President and Director of Aspreva Pharmaceuticals Corp., which was acquired by the Galenica Group in January 2008. Prior to Aspreva, Mr. Hall co-founded the life sciences practice of consulting firm Hill and Knowlton and served as Head of Global Strategic Planning for the firm’s worldwide pharmaceutical consulting practice. Mr. Hall was the Director of Corporate Affairs for the United Kingdom and Northern Europe for The Wellcome Foundation Ltd., which is now part of GSK. Additionally, Mr. Hall worked in market development with Abbott Laboratories Ltd. and was the regional sales manager with Leo Laboratories Ltd.
Mr. Hall holds a B.Sc. degree in Medical Laboratory Science from London University, and currently serves on the board of directors of iCo Therapeutics Inc., a biotechnology company. Mr. Hall has served as a member of our board of directors since October 28, 2008. Mr. Hall is also currently serving as a director of Creatus Sciences Inc., Viteris Biopharma Inc., Arius Technologies Inc. and Crailar Fibre Technologies Inc.
Dr. Kenneth J. Hillan is the CEO of Achaogen Inc. He has served as CEO and a member of the board of directors of Achaogen since October 2011. Prior to joining Achaogen, Dr. Hillan worked at Genentech Inc., a pharmaceutical company and a member of the Roche Group. Dr. Hillan worked in progressively senior roles after joining Genentech in 1994. He was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentech’s immunology, tissue growth and repair drug portfolio. Dr. Hillan also served on the board of directors of Relypsa Inc., a publicly traded biotechnology company that was acquired in 2016 by Galencia AG for $1.5 billion. Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow in the United Kingdom. Dr. Hillan is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists. Dr. Hillan has authored dozens of scientific publications and is a named inventor on approximately 50 issued patents.
Mr. Madsen is the Senior Managing Partner at BDC Capital in the Healthcare Fund and has over 20 years of senior management experience as a financial executive and venture investor. Prior to joining BDC in 2012, Mr. Madsen was the Founder and Managing Director of Physic Ventures, and Managing Director of Unilever Technology Ventures, Unilever’s North American corporate venture fund. Prior to Unilever, Mr. Madsen led Chiron Corporation’s investor communications, as Director of Investor Relations, and before moving to San Francisco, he spent five years as Partner of RBC Capital Partners’ Life Sciences Venture Fund.
Mr. Madsen currently sits on the Board of Directors of Interface Biologics, Agrisoma Biosciences, Phemi Health Systems, Xagenic and is a board observer at Chromatin. He is also a member of the selection committee of the San Francisco Canadian Technology Accelerator, a founding member of the C100 and has sat on the boards of directors of many venture capital funds and companies in the pharmaceutical and health care industries. He is a CFA charterholder and has a Bachelor of Commerce in Finance and Marketing from the University of Saskatchewan. Mr. Madsen has served as a member of our board of directors since Jan 8, 2016.
Mr. Renton has served as a member of our board of directors since February 2017. Mr. Renton served as CEO and President of
Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chairperson of the board of directors of Onyx from June
2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the
President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from December 1991 to December 1993.
Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983 prior to its acquisition by Chiron in 1991.
Mr. Renton currently serves as co-chairperson of the board of directors of Portola Pharmaceuticals Inc. where he has been a board
member since March 2010. He has also served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton
served on the boards of three biopharmaceutical companies, KYTHERA Biopharmaceuticals, Inc. (January 2015 to October 2015),
Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also
previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton
received his M.B.A., from the University of Michigan and his B.S. in Mathematics from Colorado State University.
Dr. Tehrani is one of our co-founders and currently serves as our President and Chief Executive Officer. He has been an integral part of many of our corporate achievements including raising seed and angel financing and overseeing our technical operations and patent filings. Dr. Tehrani holds both Bachelors and Masters of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his PhD degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002.
Dr. Tehrani has served as a Board Director for the Student Biotechnology Network, on the MITACS Industrial Advisory Board, and BIOTE Canada’s Industrial and Environmental Committee. Currently, he is a member of the Board of Directors of LifeSciences British Columbia, Creatus Biosciences Inc and CQDM.
Dr. Tehrani also serves as a member of the British Columbia Premier's Technology Council.
Dr. Tilley is a Managing Partner at CTI Life Sciences Fund, or CTI LSF, a Montreal-based venture capital fund investing across Canada and the United States. Since joining CTI LSF at its inception in 2006, Dr. Tilley has played a critical role in each of the fund’s investments, including Medicago Inc. (a biotechnology company acquired by Mitsubishi Tanabe in 2013) as well as Xagenic Inc. and Zymeworks Inc. Prior to joining CTI LSF, Dr. Tilley was Senior Vice President at Drug Royalty Corporation (now DRI), the world’s first private equity firm exclusively focused on royalty transactions in the biotech/pharma space. Before DRC, Dr. Tilley ran and managed a research laboratory, holding faculty positions at the NYU School of Medicine and Public Health Research Institute, New York, and on the Public Health Research Institute, or PHRI, Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the NIH Small Business Innovation Research, or SBIR, program in immunology and infectious diseases for 10 years.
Dr. Tilley holds a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine, an MBA from the University of Toronto, and is a member of the Chartered Financial Analyst, or CFA, Society of Toronto. She currently sits on the boards of Xagenic Inc., a biotechnology company, Immunovaccine Inc., PHEMI, Zymeworks Inc. and BIOTECanada, a national biotechnology industry association, and served as a board observer on Enobia Pharma Corp. prior to its acquisition by Alexion Pharmaceuticals, Inc. in 2012. Dr. Tilley has served as a member of our board of directors since June 19, 2009.
Ms. Zoth is a Certified Public Accountant and has served as Chief Financial Officer, Controller and Chief Accountant for various publicly-traded companies. Previously, Ms. Zoth acted as Chief Financial Officer for MedImmune, Inc., a publicly traded biotechnology company, which was acquired by AstraZeneca plc in June 2007. From 2000 to 2002, Ms. Zoth acted as Senior Vice President, Controller and Chief Accounting Officer of PSINet, Inc, and led the company through its 2002 restructuring in collaboration with PricewaterhouseCoopers. Ms. Zoth currently serves on the boards of numerous biopharmaceutical companies including Aeras, Orexigen Therapeutics, Inc., NewLink Genetics Corporation, Circassia Pharmaceuticals, plc and Spark Therapeutics, Inc. Previously, Ms. Zoth served on the boards of two biopharmaceutical companies, Hyperion Therapeutics, Inc. (2008-2015) and Ikaria, Inc (2008-2014). Ms. Zoth is, or has served as, the Audit Committee Chair at each of these companies. Ms. Zoth has served as a member of our board of directors since November 9, 2016.